Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium

CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change – a clinically meaningful endpoint recommended by the FDACNM-Au8 showed...
November 15, 2021 08:48 ET | Source: Clene Inc.

Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform Trial

Registration trial for CNM-Au8®, a gold nanocrystal suspensionTopline data anticipated 2H 2022World’s first ALS platform trial accelerating the path to new ALS therapies SALT LAKE CITY, Nov. 15,...
November 09, 2021 07:00 ET | Source: Clene Inc.

Clene Reports Third Quarter 2021 Operating and Financial Highlights

Recently announced top-line results from RESCUE-ALS Phase 2 trial with CNM-Au8®, a gold nanocrystal suspensionVISIONARY-MS blinded interim data show clinically relevant improvements in the modified MS...
November 02, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial

RESCUE-ALS Phase 2 Trial did not meet primary MUNIX biomarker endpoint or secondary FVC endpoint at week 36; MUNIX efficacy signal was observed at week 12 (p=0.057)MUNIX trial results demonstrated...
September 23, 2021 07:00 ET | Source: Clene Inc.

Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis

SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
September 17, 2021 07:00 ET | Source: Clene Inc.

Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021

SALT LAKE CITY, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
September 09, 2021 07:00 ET | Source: Clene Inc.

Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021

Final patient visit has been completed in its Phase 2 RESCUE-ALS study; study close-out activities have commenced90% of eligible patients are continuing to be treated under a long-term open label...
August 31, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

SALT LAKE CITY, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
August 11, 2021 07:00 ET | Source: Clene Inc.

Clene Enters into Two Leases to Materially Expand Manufacturing Capacity of its Lead Asset CNM-Au8®

SALT LAKE CITY, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
August 10, 2021 07:00 ET | Source: Clene Inc.

Clene Reports Second Quarter 2021 Operating and Financial Highlights

Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension Phase 2, placebo-controlled RESCUE-ALS trial...